Jackson 2014.
Study characteristics | |||
Patient sampling | Study design: prospective cohort study. Participants: pregnant women selected at high risk and low risk of fetal aneuploidy presenting for screening. Inclusion criteria: not reported. Exclusion criteria: not reported. | ||
Patient characteristics and setting | Number enrolled: 1228 pregnant women screened at first‐trimester, including 1184 pregnant women with normal first‐trimester ultrasound and 44 with abnormal ultrasound.
Number available for 2 x 2 table: 1161 pregnant women (subgroup of 95%).
Setting: 1 centre. South Shore Hospital in USA. Recruitment period: June 2012 to January 2013. Ethnicity: not reported. Gestational age: not reported. Median maternal age: 31.5 years. Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement) or biochemical screening or both. Language of the study: English. |
||
Index tests | gNIPT by TMPS (DANSR assay). Fetal fraction DNA: not reported. Blood samples for gNIPT were collected before reference standard. Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if FORTE risk score ≥ 1%. Commercial test: Harmony™ Prenatal Test. |
||
Target condition and reference standard(s) | Target conditions: T21, T18 and T13. Reference standards: fetal karyotype of chorionic villi or amniotic fluid, or medical record from birth. | ||
Flow and timing | Blood samples were obtained prior to the invasive procedure (reference standard). gNIPT was a second‐tier test. 67/1228 samples excluded of 2 x 2 tables, including 7 women with other abnormal ultrasound, 14 women opted for CVS only without gNIPT, 32 women declined all testing and 14 samples failed after 2 attempts during sequencing process (no gNIPT result). |
||
Comparative | |||
Aim to study | To assess the performance of nuchal translucency measurement followed by gNIPT in the first‐trimester to screen for aneuploidy in a community‐based average‐risk population. | ||
Funding source or sponsor of the study | Funding source not reported but 1 author is employed by Ariosa Diagnostics, Inc. | ||
Informations about the authors contacted | Author was contacted on: 22 February 2016 and 15 March 2016. No reply received from the author. | ||
Notes | |||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Unclear | ||
Was a case‐control design avoided? | Unclear | ||
Did the study avoid inappropriate exclusions? | Unclear | ||
Unclear | High | ||
DOMAIN 2: Index Test TMPS | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | Yes | ||
If a threshold was used, was it pre‐specified? | Yes | ||
Low | Low | ||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | Yes | ||
Low | Low | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Yes | ||
Did all analysed patients receive the reference standard? | Yes | ||
Were all patients included in the analysis? | No | ||
High |